DYN · NASDAQ · STOCK
Dyne Therapeutics, Inc.
$26.70
52W $11.17 – $27.13
62/100
$4.99B
-8.0
1.08
Is DYN Bullish or Bearish?
Bullish.
Innellis AI committee rates Dyne Therapeutics, Inc. (DYN) Buy with a composite score of 62/100
, based on 5 analysts with 60% agreement.
Last updated August 11, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +13.25 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -6.75 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
Positive signals support the current rating — vix regime is low -- calm backdrop supports risk-taking. The committee sees sufficient evidence to maintain the constructive view.
Bull & Bear Case
Bull Case
- Price structure making higher highs and higher lows — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
- Low leverage (debt-to-equity 0.15) -- balance sheet can absorb a shock — Risk
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
- News sentiment is positive (+0.33 across 3 articles, 14d) — News
Bear Case
- ROE of only -64.3% -- cheap may mean cheap for a reason — Value
- RSI at 72 is in overbought territory — Technical
- MACD histogram negative -- bearish momentum — Technical
- Weekly RSI at 84 -- overbought on the larger timeframe too — Technical
- Bollinger bandwidth of 19.4% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of August 11, 2026
Overall Committee Score
62/100
Agreement
60%
Analysts
5
Conviction
Moderate
Sector Rank
Top 34%
of 192 Healthcare peers
Value Analyst
neutral
52
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
− ROE of only -64.3% -- cheap may mean cheap for a reason
Technical Analyst
neutral
54
/ 100 · High confidence
Mixed or range-bound price action
+ Price structure making higher highs and higher lows
− RSI at 72 is in overbought territory
Risk Analyst
neutral
58
/ 100 · Moderate confidence
Moderate risk -- no single red flag, but nothing that clearly de-risks the position either
+ Low leverage (debt-to-equity 0.15) -- balance sheet can absorb a shock
− Bollinger bandwidth of 19.4% signals elevated volatility
Macro Analyst
bullish
78
/ 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst
bullish
68
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.33 across 3 articles, 14d)
Portfolio Manager
neutral
55
/ 100 · Moderate confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− 2 existing position pair(s) are highly correlated already
Technical Analysis
RSI (14)
71.9
Overbought
MACD Histogram
-0.001
Bearish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Mixed
Bollinger %B
0.86
Inside Bands
Price vs Moving Averages
EMA 9
$25.97
Above
EMA 21
$24.97
Above
EMA 50
$22.96
Above
EMA 200
$19.22
Above
Fundamental Analysis
Valuation
75
Profitability
0
Financial Health
100
Cash Flow
15
Valuation
P/E Ratio
-8.0×
P/B Ratio
6.29×
PEG Ratio
-0.56
Dividend Yield
0.00%
52W High
$27.13
52W Low
$11.17
Quality & Growth
ROE
-4590.1%
ROA
-3759.3%
Gross Margin
0.0%
Operating Margin
0.0%
Revenue Growth YoY
—
Debt / Equity
0.03
AI Fundamental Assessment
[reduced confidence: limited earnings history] P/E ratio of -8.0 (inexpensive relative to a 15-40x range); Price-to-book of 6.3x; PEG ratio of -0.6 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -45.9%; Return on assets of -37.6%; Net margin of 0.0%; Gross margin of 0.0%; Current ratio of 12.02 (healthy short-term liquidity); Debt-to-equity of 0.03; Free cash flow per share is negative (-3.02); Earnings-history trend unavailable; growth based on TTM year-over-year only.
Get the Full DYN Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →